stockrow
Friday 6 November 2026
Export MRKR’s income statement to Excel — free account
MARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.
- Revenue
- −51.0%
- EPS
- +69.0%
- Free cash flow
- −97.8%
Quarter to June 2026, against a year earlier
0.92
0.02
+2.22%
Follow MRKR
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 4 | — | — |
| (110.67%) | (68.81%) | (77.04%) | (76.87%) | ||
| (87.60%) | (59.20%) | (63.30%) | (59.33%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (566.75%) | |
Return on Tangible Assets |
(77.75%) | (72.42%) | (78.99%) | (71.57%) | |
Average Days of Receivables |
129.46 | 140.93 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.78) | (0.41) | (0.51) | |
Free Cash Flow |
(14.82) | (12.01) | (7.92) | (9.76) | |
| Other line items | |||||
Cash ROIC |
(39.69%) | (35.50%) | (26.02%) | (39.19%) | |
Accounts Receivable Turnover |
3.90 | 1.91 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
314.05% | 332.68% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
92.98% | 117.99% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
10.16% | 15.16% | 0.00% | 0.00% | |
Operating CF/Net income |
1.04 | 0.99 | 0.73 | 1.12 | |
Revenue per Share |
0.28 | 0.23 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.78) | (0.41) | (0.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 25 Oct 2026